

American  
National  
Standard

ANSI/AAMI  
ST67:2019

Sterilization of health care  
products—Requirements  
and guidance for selecting  
a sterility assurance level  
(SAL) for products labeled  
“sterile”

# Sterilization of health care products— Requirements and guidance for selecting a sterility assurance level (SAL) for products labeled “sterile”

Developed by  
Association for the Advancement of Medical Instrumentation

Approved 29 July 2019 by  
American National Standards Institute, Inc.

**Abstract:** This standard establishes requirements, guidance and a risk framework for identification of acceptable approach(es) for assurance of sterility and for selection of alternative SAL(s) or aseptic processing for health care product that cannot be terminally sterilized to achieve an SAL value of  $10^{-6}$ .

**Keywords:** sterility assurance level (SAL), terminal sterilization, aseptic processing, biologics, combination devices

## AAMI Standard

This Association for the Advancement of Medical Instrumentation (AAMI) standard implies a consensus of those substantially concerned with its scope and provisions. The existence of an AAMI standard does not in any respect preclude anyone, whether they have approved the standard or not, from manufacturing, marketing, purchasing, or using products, processes, or procedures not conforming to the standard. AAMI standards are subject to periodic review, and users are cautioned to obtain the latest editions.

**CAUTION NOTICE:** This AAMI standard may be revised or withdrawn at any time. AAMI procedures require that action be taken to reaffirm, revise, or withdraw this standard no later than five years from the date of publication. Interested parties can obtain current information on all AAMI documents by calling or writing AAMI.

All AAMI standards, recommended practices, technical information reports, and other types of technical documents developed by AAMI are *voluntary*, and their application is solely within the discretion and professional judgment of the user of the document. Occasionally, voluntary technical documents are adopted by government regulatory agencies or procurement authorities, in which case the adopting agency is responsible for enforcement of its rules and regulations.

*Published by*

AAMI  
901 N Glebe Road, Suite 300  
Arlington, VA 22203

© 2019 by the Association for the Advancement of Medical Instrumentation

All Rights Reserved

This publication is subject to copyright claims of AAMI. Publication, reproduction, photocopying, storage, or transmission, electronically or otherwise, of all or any part of this document without the prior written permission of the Association for the Advancement of Medical Instrumentation is strictly prohibited by law. It is illegal under federal law (17 U.S.C. § 101, et seq.) to make copies of all or any part of this document (whether internally or externally) without the prior written permission of the Association for the Advancement of Medical Instrumentation. Violators risk legal action, including civil and criminal penalties, and damages of \$100,000 per offense. For permission regarding the use of all or any part of this document, complete the reprint request form at [www.aami.org](http://www.aami.org) or contact AAMI at 901 N Glebe Road, Suite 300, Arlington, VA 22203. Phone: (703) 525-4890; Fax: (703) 276-0793.

Printed in the United States of America

ISBN 978-1-57020-727-3

## Contents

Page

Committee representation.....	iv
Foreword.....	vii
Introduction.....	viii
1 Scope.....	1
2 Normative references.....	1
3 Definitions.....	2
4 Determination of approach for assurance of sterility.....	4
5 Approaches to assure sterility other than use of an SAL value of $10^{-6}$ .....	8
<b>Annexes</b>	
A Background and historical application of sterility assurance.....	10
B Modification strategies to consider in order to achieve terminal sterilization at an SAL value of $10^{-6}$ .....	12
C Risk management considerations if an SAL value of $10^{-6}$ cannot be achieved.....	18
D Examples of risk management considerations to select an approach to assure sterility.....	23
Bibliography.....	30

## Committee representation

### Association for the Advancement of Medical Instrumentation

#### Assurance of Sterility Working Group

This standard was developed by the AAMI Assurance of Sterility Working Group under the auspices of the AAMI Sterilization Standards Committee. Approval of the standard does not necessarily mean that all working group members voted for its approval. At the time this standard was published, the **AAMI Assurance of Sterility Working Group** had the following members:

*Cochairs:* Byron Lambert, PhD  
Trabue Bryans

*Members:* Christopher Anderson, Johnson & Johnson  
Ed Arscott, NAMSA  
Jen Aleson, Quality, Microbiology & Sterilization Services LLC  
Jenny Berg, Sterilucent Inc  
Carolyn Braithwaite-Nelson, Spectranetics Corporation  
David Brodersen, LexaMed Ltd  
Trabue Bryans, BryKor LLC  
Glenn Calvert, Tech Group North America  
Tim Carlson, Becton Dickinson & Company  
Emily Craven, Mevex Corporation  
Sophia Czechowicz, Advanced Sterilization Products  
Brian Drumheller, Femasys Inc  
Gordon Ely, GEM Consulting  
Dan Floyd, DuPont Tyvek Medical and Pharmaceutical Protection  
Becky Gilsdorf, Healthmark  
Zory Glaser, PhD, Johns Hopkins University-School of Public Health  
Doug Harbrecht, Sterility Assurance LLC  
Fatima Hasanian, Sotera Health  
Jason Hedrick, Medtronic Inc Campus  
Betty Howard, STERIS Corporation  
Nupur Jain, Intuitive Surgical Inc  
Valerie Kozik, Press Ganey/Sovrin  
Byron Lambert, PhD, Abbot Laboratories  
Jack LeClair  
David Lin, PhD, Taiwan Advanced Sterilization Technology Inc  
Michelle Luebke, Baxter Healthcare Corporation  
Tania Lupu, Casp Medical Inc  
Jeff Martin, Sterilization and Quality System Consulting LLC  
Patrick McCormick, Bausch & Lomb Inc  
Jami McLaughlin, Boston Scientific Corporation  
Vanessa Morphy-Simard, TSO3 Inc  
Gerry O'Dell, Gerry O'Dell Consulting  
John Olson, Cantel Inc  
Cristina Parente, Ecolab  
Cristina Romero-Waas, BSI Healthcare  
Bobby Rupert, WL Gore & Associates Inc  
Manny Saavedra, Avanos Medical  
Jessica Schoelerman, Accuratus Labs Services  
Harry Shaffer, Sterilization Consulting Services  
Myra Smith, FDA/CDRH  
Michael Sprague, Ethide Laboratories Inc  
Sopheak Srun, Quality Tech Services LLC  
Liz Steiner, IUVO BioScience  
Leslie Tavares, WuXi AppTec Inc  
Don Tumminelli, HIGHPOWER Validation Testing & Lab Services Inc  
Lisa Wakeman, Indiana University Health  
Wendy Wangsgard, Nelson Laboratories LLC

Beverly Whitaker, Indigo Consulting Group LLC  
Kristy Yates, 3M Healthcare  
Roberto Zumbado, Philips

**Alternates:** Stacy Bohl, Boston Scientific Corporation  
Brad Catalone, PhD, TSO3 Inc  
Phil Cogdill, Medtronic Inc Campus  
Chris Coker, Advanced Sterilization Products  
Sean Colwell, WuXi AppTec Inc  
Mary Ann Drosnock, Healthmark  
Mark Duro, Cantel Inc  
Kevin Grum, DuPont Tyvek Medical and Pharmaceutical Protection  
Nichole Jackson, Ecolab  
Satu King, Spectranetics Corporation  
Mark Krocko, Mevex Corporation  
Jim Kulla, LexaMed Ltd  
Alison Laughlin, Baxter Healthcare Corporation  
Gerry McDonnell, PhD, Johnson & Johnson  
Nicole McLees, 3M Healthcare  
Brian Nissen, Quality Tech Services LLC  
Nicole Pasquino, Case Medical Inc  
Janelle Pence, WL Gore & Associates  
Kyrstan Polaski, STERIS Corporation  
Jason Pope, Sotera Health  
Nancy Rakiewicz, IUVO BioScience  
Victoria Rodriguez, FDA/CDRH  
Tyrone Rouse, Owens & Minor  
Mike Schoene, Bausch & Lomb Inc  
Mary Sheehan, BSI Healthcare  
Tajinder Uppal, NAMSA  
Hemant Vekaria, Abbott Laboratories  
Brian Wallace, Intuitive Surgical Inc

---

NOTE—Participation by federal agency representatives in the development of this standard does not constitute endorsement by the federal government or any other agencies.

---

At the time this document was published, the **AMI Sterilization Standards Committee** had the following members:

**Cochairs:** Michael Scholla, PhD  
Patrick Weixel, FDA/CDRH

**Members:** Anas Aljahn, SteriPro Canada Inc.  
Brett Anderson, Cochlear Ltd  
Richard Anagnost, Steris Corporation  
Marie Brewer  
Traudie Bryans, BryKor LLC  
John Burdach, Nanosonics Limited  
Tim Carlson, Becton Dickinson & Company  
Phil Cogdill, Medtronic Inc Campus  
Lena Cordie, Qualitas Professional Services LLC  
Jackie Daley  
Gordon Ely, GEM Consulting  
Lisa Foster, Aduvo QS & SA Consulting  
Dan Fowler, WuXi AppTec  
Joel Gorski, NAMSA  
Joyce Hansen, Johnson & Johnson  
Stephanie Homuth  
Gail Horvath, ECRI Institute  
Clark Houghtling, Cosmed Group Inc

Sue Klacik, IAHCMM  
Erin Kyle, Association of periOperative Registered Nurses  
Byron Lambert, Abbott Laboratories  
Michelle Luebke, Baxter Healthcare Corporation  
Patrick McCormick, Bausch & Lomb Inc  
Leslie Nichols, Mayo Clinic  
Gerry O'Dell, Gerry O'Dell Consulting  
David Pickard, BSI Healthcare  
Adrian Ponce, Verrix LLC  
Janet Prust, 3M Healthcare  
Nancy Rakiewicz, IUVO BioScience  
Michael Scholla, PhD, DuPont Tyvek Medical and Pharmaceutical Protection  
Linda Schultz, Northside Hospital Surgical Services Atlanta  
Kristen Singleton, Getinge USA  
Joan Spear, B Braun of America Inc  
Patrick Weixel, FDA/CDRH  
Sid Wiggs  
Stephen Yeadon, Boston Scientific Corporation  
Bill Young, Sotera Health  
Roberto Zumbado, Philips

*Alternates:* Stacy Bohl, Boston Scientific Corporation  
Greg Crego, IUVO BioScience  
Dan Floyd, DuPont Tyvek Medical and Pharmaceutical Protection  
Bob Marrs, B Braun of America Inc  
Gerry McDonnell, PhD, Johnson & Johnson  
David McGoldrick, Abbott Laboratories  
Kim Patton, Becton Dickinson & Company  
Christine Render, Cosmed Group Inc  
Mike Sadowski, Baxter Healthcare Corporation  
Mark Smith, Getinge USA  
Craig Wallace, 3M Healthcare  
Lisa Ward, STERIS Corporation  
Jill Warren, WuXi AppTec  
Martell Winters, Sotera Health  
Jon Wood, IAHCMM

---

NOTE—Participation by federal agency representatives in the development of this standard does not constitute endorsement by the federal government or any of its agencies.

---

## Foreword

This standard was developed by the AAMI Assurance of Sterility Working Group under the auspices of the AAMI Sterilization Standards Committee.

The purpose of this standard, for product to be labeled as sterile, is to provide requirements, guidance and a risk framework for identification of acceptable approach(es) for assurance of sterility and for selection of alternative SAL(s) or aseptic processing for health care products that cannot be terminally sterilized to achieve an SAL value of  $10^{-6}$ .

Compared with the previous edition of the standard, changes in ANSI/AAMI ST67:2019 include:

- addition of a section of alternate SAL;
- addition of a section on aseptic processing;
- inclusion of a new annex on modification strategies to achieve terminal sterilization at an SAL of  $10^{-6}$ ;
- new tables for risk aspects to consider for individual patients; and
- new tables for product SAL requirements.

This standard reflects the conscientious efforts of health care professionals, in cooperation with medical device and equipment manufacturers, to develop recommendations for quality systems for the processing of medical devices. It is not intended that these recommendations be construed as universally applicable in all circumstances. Also, it is recognized that in many cases these recommendations might not be immediately achievable. Therefore, the document should be used to guide personnel towards desirable performance objectives, and all of its provisions should be considered and applied in the light of professional judgment and experience.

As used within the context of this document, “shall” indicates requirements strictly to be followed to conform to the standard. “Should” indicates that among several possibilities one is recommended as particularly suitable, without mentioning or excluding others, or that a certain course of action is preferred but not necessarily required, or that (in the negative form) a certain possibility or course of action should be avoided but is not prohibited. “May” is used to indicate that a course of action is permissible within the limits of the standard. “Can” is used as a statement of possibility and capability. Finally, “must” is used only to denote “unavoidable” situations, including those mandated by government regulation.

The provisions of this standard should be reviewed routinely by departmental managers and quality management representatives and adapted to the needs of their particular institutions. Written policies, procedures, and work instructions should be developed and implemented in consultation with appropriate hospital committees (e.g., safety, infection prevention and control, and hazardous materials).

The concepts incorporated in this standard should be considered flexible and dynamic. The recommendations set forth in this document are reviewed and updated periodically to assimilate progressive technological developments. AAMI policies and procedures require that AAMI standards and recommended practices be reviewed and, if necessary, revised at least once every five years.

Suggestions for improving this standard are invited. Comments and suggested revisions should be sent to Technical Programs, AAMI, 900 N. Glebe Rd, Suite 300, Arlington, VA 22203.

---

NOTE—This foreword does not contain provisions of the AAMI Standard, *Sterilization of health care products—Requirements and guidance for selecting a sterility assurance level (SAL) for products labeled “sterile”* (AAMI ST67:2019), but it does provide important information about the development and intended use of the document. American National Standard ANSI/AAMI ST67:2019.

---

## Introduction

Sterility (or the state of being sterile) is defined as being free of viable microorganisms. The sterility of a health care product can be achieved through validation and control of a terminal sterilization process (or processes), through aseptic processing (i.e., product components are separately sterilized prior to final aseptic assembly) when terminal sterilization is not feasible, or a combination of the two processes. Regardless of the process, there are other considerations to assuring that the outcome is a sterile product. Some of these considerations are product design, the manufacturing process, quality control of raw materials, process control and the method used to qualify the process. For health care products labeled 'sterile' attention to product and sterile barrier system or container characteristics, manufacturing facilities, controls, and other aspects of a quality system are required as defined in standards and government regulations.<sup>1</sup>

The AAMI/ISO standards recognize that there are certain processes used in manufacturing for which the results cannot be fully verified by subsequent inspection and testing of the product. Examples of such processes are those that reduce the risk of microbial contamination, e.g., terminal sterilization and aseptic processing. For this reason, terminal sterilization and aseptic processing processes must be validated and monitored.

Healthcare products produced under standard manufacturing conditions in accordance with requirements for quality management systems typically have microorganisms on them and are nonsterile. The microbial load on product can be reduced by controlling bioburden of raw materials, personnel and the manufacturing environment in conjunction with:

- a) a terminal sterilization process; and/or
- b) a combination of component (e.g., raw materials, drug or biologic product, containers and/or devices) sterilization and aseptic processing.

During terminal sterilization processes, the manufactured product within its sterile barrier system or container is sterilized using a defined microbicidal process. The purpose of terminal sterilization is to achieve sterility by inactivating product bioburden using a validated process. Inactivation studies with microorganisms exposed to sterilizing agents (e.g., dry heat, moist heat, ethylene oxide, or radiation) approximate an exponential rate of kill. Mathematically there is always a finite probability that a microorganism might survive regardless of the extent of treatment applied. For a given extent of treatment, the probability of survival is influenced by the number and resistance of microorganisms and the environment in which the microorganisms exist during treatment. Sterility in these cases is defined in terms of the probability of a viable microorganism on/in the product following sterilization. This mathematical probability is commonly referred to as a sterility assurance level (SAL).

The purpose of this standard, for products to be labelled as sterile, is to provide requirements, guidance and a risk framework for identification of acceptable approach(es) for assurance of sterility and for selection of alternative SAL(s) or aseptic processing for health care products that cannot be terminally sterilized to achieve an SAL value of  $10^{-6}$ .

---

<sup>1</sup> For medical devices, refer to U.S. Food and Drug Administration's (FDA's) 21 CFR 820, International Organization for Standardization's (ISO's) ISO 13485, and European Medical Device Regulation. ANSI/AAMI/ISO 13485 is an application of the ISO 9000 series of quality management system standards.

For pharmaceutical products, refer to U.S. FDA's 21 CFR 210/211 and European Medical Device Regulation and biologics U.S. FDA's 21 CFR 600/601

# Sterilization of health care products— Requirements and guidance for selecting a sterility assurance level (SAL) for products labeled “sterile”

## 1 Scope

### 1.1 Inclusions

**1.1.1** This standard specifies requirements and provides guidance on selecting approaches to establish assurance of sterility for a health care product labelled as “sterile.” Approaches to assurance of sterility include terminal sterilization at the accepted SAL appropriate for the product (e.g.,  $10^{-6}$  or  $10^{-3}$ ), terminal sterilization at alternative SALs and aseptic processing.

**1.1.2** This standard as it pertains to terminal sterilization applies to sterilization processes in which microorganisms are inactivated by physical and/or chemical means.

### 1.2 Exclusions

**1.2.1** This standard does not address health care products that are not labeled “sterile.” For example, nonsterile health care products that possess antimicrobial properties or contain preservatives for the control of microbial levels are not addressed.

**1.2.2** This standard is not applicable to the sterilization of used or reprocessed health care products.

**1.2.3** This standard is not applicable to sterilization of health care products by filtration.

**1.2.4** This standard does not specify requirements for development, validation and routine control of a process for inactivating the causative agents of spongiform encephalopathies such as scrapie, bovine spongiform encephalopathy and Creutzfeldt-Jakob disease. Specific recommendations have been produced in particular countries for the processing of materials potentially contaminated with these agents.

NOTE—See also ISO 22442-1, ISO 22442-2 and ISO 22442-3.

**1.2.5** This standard does not attempt to define what is considered an acceptable level of risk to justify an alternative SAL. This risk assessment must be based on valid clinical and/or scientific data. As such, what is considered an acceptable level of risk might vary from product to product.

## 2 Normative references

The following normative references contain provisions that, through reference in the text, constitute provisions of this standard. For any dated reference, subsequent amendments to or revisions of the reference do not apply. However, parties to agreements based on this standard are encouraged to investigate the possibility of applying the most recent editions of the normative references indicated below.

ANSI/AAMI/ISO 14971, *Medical devices—Application of risk management to medical devices*

U.S. FOOD AND DRUG ADMINISTRATION. Current good manufacturing practice in manufacturing, processing, packing, or holding of drugs; general. Code of Federal Regulations, Title 21, Part 210/211.

U.S. FOOD AND DRUG ADMINISTRATION. Biological products: General. Code of Federal Regulations, Title 21, Part 600/601.